Virbac cuts revenue forecast on U.S., Chile market conditions

September 19, 2016 4:48 PM

12 0

French veterinary pharmaceutical firm Virbac (VIRB.PA) reported a jump in first-half earnings on Monday but trimmed its 2016 revenue growth forecasts due to difficulties in the United States and Chile, as well as a negative currency impact.

The company, which sells drugs for animals in more than 100 countries, is now aiming for organic revenue growth of 4.5-6.5 percent in 2016 compared with a previous target of 7 percent, it said in a statement.

Read more

To category page